[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3742 Introduced in House (IH)]
<DOC>
118th CONGRESS
1st Session
H. R. 3742
To direct the Comptroller General of the United States to evaluate the
Federal Government's collection and sharing of public health data to
respond to public health emergencies.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 26, 2023
Mr. Peters (for himself and Mr. Guthrie) introduced the following bill;
which was referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To direct the Comptroller General of the United States to evaluate the
Federal Government's collection and sharing of public health data to
respond to public health emergencies.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. STUDY ON FEDERAL PUBLIC HEALTH DATA COLLECTION AND SHARING.
(a) In General.--The Comptroller General of the United States shall
evaluate the Federal Government's collection and sharing of public
health data to respond to public health emergencies involving
infectious disease outbreaks or biological threats, such as the COVID-
19 pandemic, and provide as appropriate recommendations to address the
collection and sharing of public health data.
(b) Topics.--The evaluation under subsection (a) shall include a
review of what is known about--
(1) the authorities, policies, and operational tools used
by the Secretary of Health and Human Services to collect public
health data from, and share public health data with, other
Federal agencies, State, local, territorial, and Tribal
governments, and other partners, including--
(A) how those authorities, policies, and tools were
used during the COVID-19 public health emergency;
(B) how Federal funds were expended for the purpose
of public health data collection and sharing during the
COVID-19 public health emergency;
(C) any challenges posed by redundant data
reporting requirements placed on State, local,
territorial, and Tribal governments and other partners
during the COVID-19 public health emergency, including
whether these requirements conflicted with the needs of
State, local, territorial, or Tribal communities or
other partners; and
(D) any publicly available resources to track how
public health data is being collected, shared, and used
with other Federal agencies, State, local, territorial,
and Tribal governments, and other partners;
(2) any limitations on the authorities, policies, and tools
used during declared public health emergencies, including
throughout the COVID-19 public health emergency, that affect
the Federal Government's ability to respond to declared public
health emergencies;
(3) any redundancy or overutilization in the authorities,
policies, and tools used during declared public health
emergencies, including throughout the COVID-19 public health
emergency, including whether any redundant data reporting
requirements conflicted with the needs of State, local,
territorial, or Tribal communities or other partners; and
(4) the Federal Government's data collection, sharing, and
epidemiological modeling during the COVID-19 public health
emergency compared with the data collection, sharing, and
epidemiological modeling of nonprofit and private sector
stakeholders, including how the Secretary developed tools, or
used already existing tools, to collect, share, model, and
disseminate public health data in comparison to the development
of tools and use of existing tools for such purposes by the
nonprofit and private sectors.
(c) Report to Congress.--Not later than 18 months after the date of
enactment of this Act, the Comptroller General of the United States
shall submit a report to the Congress on the results of the evaluation
under subsection (a).
(d) Definition.--In this section, the term ``other partners''
includes--
(1) hospitals and physician practices;
(2) health systems and health plans;
(3) manufacturers and distributors; and
(4) clinical laboratories.
<all>